

Knowledge Systems @ DFCI

Ethan Cerami, Ph.D.

Director, Knowledge Systems Group



James Lindsay, Ph.D.
Associate Director, Knowledge Systems Group

cBioCenter @ DFCI

DFCI Knowledge Systems Group, cBioCenter

Applied genomics software and data science group.

Building genomic software to enable:


- cancer genomics research
- clinical application of genomic data.



Part of the new cBioCenter @ DFCI (Head: Chris Sander)

Enterprise Genomics and Data Science @ DFCI





Data acquisition

Data utilization

Highlighted projects

Data utilization

- cBioPortal
- MatchMiner
- Insight engine


Data acquisition

- cBioOne
- AACR GENIE
- Intel CCC



about

- Founded in 1947 by Sidney Farber
- > 4,500 employees
- > 450,000 patient visits / yr
- 900 clinical trials
 - > 500 treatment trials
- percent_research <- 0.5
- percent_clinical <- 0.5



Sidney Farber, MD, with a young patient

Enterprise genomics: PROFILE

- 15,927 patients sequenced
- Targeted DNAseq
- 447 genes / regions targeted
- CLIA-certified


DANA-FARBER/BRIGHAM AND WOMEN'S



CANCER CENTER







cBioPortal, Insight Engine, MatchMiner

DATA UTILIZATION




cBioPortal












http://cbioportal.org





R package


Installation

- 1. The CDGS-R package currently only works with R Version 2.12 or higher.
- 2. Then install the cgds-R package from within R: install.packages('cgdsr')


Example usage


```
# Create CGDS object
mycqds = CGDS("http://www.cbioportal.org/public-portal/")
test(mycgds)
# Get list of cancer studies at server
getCancerStudies(mycgds)
# Get available case lists (collection of samples) for a given cancer study
mycancerstudy = getCancerStudies(mycgds)[2,1]
mycaselist = getCaseLists(mycgds,mycancerstudy)[1,1]
# Get available genetic profiles
mygeneticprofile = getGeneticProfiles(mycgds,mycancerstudy)[4,1]
# Get data slices for a specified list of genes, genetic profile and case list
getProfileData(mycgds,c('BRCA1','BRCA2'),mygeneticprofile,mycaselist)
# Get clinical data for the case list
myclinicaldata = getClinicalData(mycgds,mycaselist)
# documentation
help('cgdsr')
help('CGDS')
```

New Architecture



Virtual Cohorts








DFCI Insight Engine

http://insight.dfci.harvard.edu



Profile + RHP Data

De-identified clinical data

GENIE Data

Weekly Updates



Reproducible
Pipelines +
Jupyter
Notebooks

Community Driven

Reports

Mutation Hotspots

Clinical Actionability

Trial Enrollment

Germline Analysis


Patient Similarity

Network Analysis

Mutational Load


Future Profile Papers

Compute, data and code in same place




Remove barriers for data science

1) Create new notebook in language of choice



3) ... science?




2) Pull in data via programmatic interface

```
genomic_df = data.get_genomic_df()
clinical_df = data.get_clinical_df()
cna_df = data.get_cna_df()
cna_df=cna_df.set_index('SAMPLE_ID')
merged_df = genomic_df.join(clinical_df, on="Tumor_Sample_Barcode")
```

MatchMiner

MatchMiner: Open Source Clinical Trial Matching Platform



Patient View – Trial Matches



Colorectal Adenocarcinoma

Invasive Breast Carcinoma

PIK3CA p.H1047R

Gene-Level Match

Tier 4

HOME DASHBOARD **CLINICAL TRIALS**



Cancer

Institute

MATCHING Y



OPEN TO

ACCRUAL


/ MATCHMINER / DASHBOARD / PATIENT RECORD PATIENT TRIAL MATCHES ONCOPANEL Smith[Fake], Raquel Clinical trial matches MR-0657 MRN MatchMiner has identified 5 potential precision medicine clinical trial matches based on genomic profiling results Date of 27 Jan 1958 obtained from OncoPanel. Birth TRIAL All trials within MatchMiner have been expertly curated to capture genomic and basic clinical eligibility details, and **MATCHES** Breast Invasive Primary matches have been computed based on the patient's genomic profile, tumor type, age, and sex. Cancer Ductal Type Carcinoma As these criteria represent only a subset of all trial eligibility criteria, additional investigation and screening should be conducted to determine final eligibility. Biopsy Site Breast **Biopsy Site** Unspecified Results Type Sample ID BRCA-Disease Coordinating Genomic match ↑ Protocol # **DFCI Trial Status** METABRIC-S1-Center Center MB-0657 Report Date 11 Feb 2013 TASELISIB+FULVESTRANT VS PLACEBO+FULVESTRANT FOR BRCA DF/HCC Dana-Farber **OPEN TO** PIK3CA p.H1047R Breast Cancer Variant-Level Protocol No: 15-153 ACCRUAL Cancer Institute Match **FILTERS** Principal Investigator: Krop, Ian E Tier 4 \vee Gene (Mutant) wt PIK3CA **Invasive Breast Carcinoma Locally Advanced** PIK3CA Adults ☐ PIK3CA (4) Metastatic **FULVESTRANT PLACEBO TASELISIB** Recurrent Phase III Gene (Wildtype) WT KRAS (1) LETROZOLE +/- BYL719 OR BUPARSILIB FOR HER2-NEGATIVE BREAST CANCER DF/HCC Dana-Farber **OPEN TO** PIK3CA p.H1047R **Breast** Cancer Protocol No: 14-202 Gene-Level Match ACCRUAL WT PIK3CA (3) Cancer Institute Tier 4 Principal Investigator: Mayer, Erica L WT TP53 (1) \checkmark wt PIK3CA **Breast** Untreated Localized **Locally Advanced** Tumor Type BUPARLISIB **BYL719 LETROZOLE** Phase II ☐ All Solid Tumors (2) Breast (2) Simulated Data

GDC-0032 + DOCETAXEL OR PACLITAXEL FOR BREAST

Protocol No: 13-123

Principal Investigator: Krop, Ian E

Trial centric – Create filter




Clinical Trial Markup Language

```
Clinical Trial Details
nct_id: NCT02097225
nct purpose: This phase I trial studies the side effects ...
phase: I
protocol id: 6534
protocol_no: 14-186
protocol_target_accrual: 32
protocol_type: Treatment
short title: AT13387 W/ DABRAFENIB + TRAMETINIB IN BRAF-MUTANT MELANOMA
status: Open to Accrual
treatment_list:
                                                                  Eligibility Criteria
  step:
 - arm:
   match:
   - and:
      - and:
                                           Genomic Criteria
        - or:
          - genomic:
             hugo symbol: BRAF
             protein_change: p.V600E
             variant_category: Mutation
          - genomic:
             hugo symbol: BRAF
             protein change: p.V600K
             variant_category: Mutation
        - genomic:
           hugo symbol: KRAS
           wildtype: true
        - genomic:
           hugo_symbol: NRAS
           wildtype: true
                                            Clinical Criteria
       clinical:
          age numerical: '>=18'
         oncotree primary diagnosis: SOLID
```


MatchMiner usage stats

138 Trials, 675 register oncologists, 125 clinical trial investigators




Search Terms (July)	
Term	Count
EGFR	6
16-494	4
16-711	3
demetri	3
(cdkn2a)	2
(cdkn2a,cdkn2b)	2
(cdkn2b)	2
(pik3ca)	2
(pik3ca,All solid tumors)	2
(pik3ca,All solid tumors,Open to Accrual)	2

Trial complexity of 138 curated trials



Genomic criteria overview



cBioOne, Intel CCC, GENIE

DATA ACQUISITION



cBioOne

cBioPortal "as a service"

- for individual investigators
- for disease centers



Profile Data

Other Genomic Data

Clinical Data







Secure Live Link File Server

Validate, Merge + De-Identify




Private to Group


Shared @ DFCI

7 Pls / Groups Now Active


AACR GENIE: First Data Release!




GENIE Landscape



Landscape of Clinical Actionability



Intel Collaborative Cancer Cloud




CCC is an <u>open</u> platform, enabling community best practice precision medicine analytics






Unique Aspect of Intel CCC: Secure joint computation



Motivation: Mutation Hotspots

Mutation Hotspot


- a specific amino acid position that is mutated more frequently than expected by chance.
- -likely indicative of oncogenic activity.



Example Mutation Hotspots in PIK3CA (Pan-Cancer)

Motivation: Long Tail of Mutation Hotspots

"85% of all hotspots identified were mutated in less than 5% of tumors"



"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity". Chang et al. 2016

Can be identified within a single cancer type or via pan-cancer analysis.

Gene Overlap of Private Data Sets



AKT1

ERBB2

KRAS

MET

NF1


PIK3CA

PIK3R1

PTEN

RB1

TP53



DFCI/OHSU DFCI/OICR

AKT2 AKT3 ALK **BRAF** CDK4 CDKN2A DDR2 **EGFR** FGFR1 FGFR3 GNA11 **GNAQ GNAS HRAS** KDR KIT MAP2K1 **NRAS**

BRCA1
BRCA2
CBLB
CDH1
CDKN1B
EPHA5
GATA3
MAP2K4
MAP3K1
MYB
RUNX1
SF3B1
STAG1

TLR4

ARID1A

NTRK2 NTRK3 NOTCH1 RET STK11

TSC1

TSC2 VHL

Full Gene Set Overlap

Present at all Centers

AKT1

ERBB2

KRAS

NF1


PIK3CA

PIK3R1

PTEN

RB1

TP53



Acknowledgements

Knowledge Systems


















cBio @ MSKCC

Nikolaus Schultz JianJiong Gao Benjamin Gross

MatchMiner

Bruce Johnson Drew Memmott Geoffrey Shapiro George Demetri Khanh Do Steve DuBois Erica Woulf Adem Albayrak Susan Barry

The Hyve

Sjoerd van Hagen Pieter Lukasse Sander de Ridder Fedde Schaeffer Bernd van der Veen

DFCI / BWH

Barrett Rollins
Laura MacConaill
Jane Song
Matt Ducar
Priyanka Shivdasani
Lynette Sholl
Neal Lindeman
Stacy Gray
Eliezer Van Allen